AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03676790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group IV
Description: Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius).
Study NCT04207853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration em NDM
Description: The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
Study NCT04207853 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vibration sham em NDM
Description: Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
Study NCT01680406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Study NCT01680406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Study NCT03676790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group V
Description: Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius).
Study NCT00730652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1411
Description: Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
Study NCT00762411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY450139
Description: Administered orally once daily.
Study NCT00762411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily.
Study NCT03508154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Meal 1
Description: carbohydrate test meal
Study NCT03508154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Meal 2
Description: carbohydrate test meal
Study NCT03508154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Nutritional Product
Description: ready to drink nutritional formulation
Study NCT02682108 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diffusion-weighted magnetic resonance imaging (DW-MRI)
Description: Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
Study NCT02979041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive virtual reality training
Description: The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.~The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion.
Study NCT02979041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: physiotherapy and medical care as provided currently
Study NCT03028155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin: BSA-based HIPEC
Description: oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
Study NCT03028155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin: Concentration-based HIPEC
Description: oxaliplatin: 230 mg/L
Study NCT00337558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: tablet
Study NCT00337558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simplified bladder training
Description: Instructions
Study NCT01652508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants in the control group are provided a self-help leaflet on smoking cessation only
Study NCT01652508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
Study NCT05253430 — intervention group
Intervention type: PROCEDURE
Intervention: Lymphadenectomy type
Description: D1 vs D2 lymph node dissection
Study NCT02784496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term Follow-up
Description: Undergo follow-up assessment
Study NCT02784496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04113616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
Study NCT04113616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine is an anti-cancer chemotherapy drug taken via injection.
Study NCT04113616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is an anti-cancer chemotherapy drug taken via injection.
Study NCT02784496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT01689649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: The patients will receive topiramate tablet twice daily orally up to 16 weeks.
Study NCT00619918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized 3% saline
Description: 4 ml inhaled q8h
Study NCT00619918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized 0.9% saline
Description: normal saline
Study NCT06613919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tuberculosis Treatment
Description: Standard, weight adjusted anti-TB therapy for six months
Study NCT06613919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Tuberculosis Treatment
Description: Standard, weight-adjusted anti-TB therapy for nine months
Study NCT06615336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Sleep retraining
Description: Intensive Sleep Retraining treatment consisted of 42 sleep onset trials over a 21-hour sleep deprivation period
Study NCT06615336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation
Description: Total Sleep Deprivation treatment consisted of an equivalent 21-hour sleep deprivation period without sleep onset trials
Study NCT01350154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 20 mg in gelatine capsules, oral, three times daily
Study NCT01350154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose monohydrate oral in gelatine capsules, 3 times daily
Study NCT00032032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00032032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00032032 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01573351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Study NCT02302716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered SC
Study NCT02302716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LANTUS®
Description: Administered SC
Study NCT02302716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antihyperglycemic Medication
Description: Administered as per standard-of-care.
Study NCT02302716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antihyperglycemic Medication
Description: Administered as per standard-of-care.
Study NCT04568577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tape with tension
Description: The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.
Study NCT04568577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tape without tension
Description: Bandaging applications will be weekly, for five weeks, without tensioning the tape.
Study NCT04309994 — intervention group
Intervention type: OTHER
Intervention: Myocardial protection system (MPS)
Description: cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
Study NCT01573351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT01573351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon Alfa-2a
Study NCT01573351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT03964805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20% oxygen
Description: culture excusively at 20% O2 (Day 0 to Day 6)
Study NCT03964805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% oxygen
Description: culture excusively at 5% O2 (Day 0 to Day 6)
Study NCT03315221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product
Description: HMF with added lipids - Intervention group
Study NCT03315221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control product
Description: Commercially available HMF (without lipids) - control group
Study NCT03964805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20 % and 5 % oxygen
Description: culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)
Study NCT01330706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polihexanide
Description: The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
Study NCT02022631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative summary of findings table format
Description: Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
Study NCT02022631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current summary of findings table format
Description: Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
Study NCT02395016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
Study NCT02395016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
Study NCT02395016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
Study NCT02395016 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
Study NCT01998815 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Roux-en-Y gastric bypass surgery
Study NCT01070758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel
Description: The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
Study NCT04045795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984 IV
Description: Pharmaceutical form: solution~Route of administration: intravenous
Study NCT04045795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT04309994 — intervention group
Intervention type: OTHER
Intervention: Cardioplexol
Description: cardioplegia solution
Study NCT04045795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT04045795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984 SC
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT04276012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Description: Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
Study NCT04045795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational injector device
Description: Subcutaneous administration
Study NCT04604158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elly Mobile Phone Application
Description: The Elly mobile phone application delivers daily audio recording aimed at reducing anxiety, stress, loneliness, and social isolation.
Study NCT02832167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02760355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90 mg/Sofosbuvir 400 mg
Description: Oral administration on one fixed dose combination tablet for 12 weeks
Study NCT02760355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients \<75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks.
Study NCT01294449 — intervention group
Intervention type: DEVICE
Intervention: MADIT-CRT ICD
Description: Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
Study NCT01294449 — intervention group
Intervention type: DEVICE
Intervention: MADIT-CRT CRT-D
Description: Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
Study NCT00218335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
Study NCT03436836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery
Study NCT03436836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine, bupivacaine, hyaluronidase , saline
Description: lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
Study NCT00218335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
Study NCT01677650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
Study NCT01677650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
Study NCT03885336 — intervention group
Intervention type: OTHER
Intervention: No Interventions
Description: There are no interventions in this study. Participants are observed.
Study NCT02566096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine
Description: compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
Study NCT02566096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine
Description: compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
Study NCT03904836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Description: 5 milligrams per kilogram intravenous for one dose
Study NCT00652002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Study NCT00652002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Study NCT00652002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Study NCT02687789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device: WO3191
Description: application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)